Integrative Phenomics and Sorbonne University, Inserm, and APHP announce PINEAPPL: a project generating personalized nutrition approaches to prevent cardiometabolic diseases and risks

Paris, April 4, 2024

Integrative Phenomics, a French SME based in Paris, developing innovative and evidenced-based models and solutions in precision and personalized nutrition, and the NutriOmics Laboratory (Sorbonne University, the French National Institute of Health and Medical Research (Inserm), the Greater Paris University Hospitals (APHP)) a group led by Prof. Karine Clément renowned for its clinical research in nutrition and metabolic diseases and related complications, have announced a groundbreaking collaborative project. The project, PINEAPPL, an acronym for “PrecIsion Nutrition and cardiometabolic diseAses Prevention Platform” is financed by the French Public Investment Bank (Banque Publique d’Investissements, BPIFRANCE) as part of France 2030’s initiative for “Innovating to succeed in agroecological and food transitions”. The PINEAPPL project is set to revolutionize personalized nutrition aimed at cardiometabolic disease management and prevention.

Bridging the Gap Between Research and Real-World

The collaboration aims to link the crucial gap between extensive research development, proof of concept stages, and their practical, market-ready application. By combining Integrative Phenomics’ industry-leading expertise in personalized nutrition models and user-facing solutions with the NutriOmics Laboratory’s excellence in understanding metabolic disease complexity, the project promises to usher in a new era of personalized nutrition through the development of a Personalized Nutrition Platform to prevent Cardiometabolic Diseases: The PINEAPPL platform.

Personalized Nutrition at the Forefront

PINEAPPL represents a commitment to advance technological solutions and the understanding of low-grade chronic inflammation in metabolic disease management and prevention. Cardiometabolic diseases, which encompasses multiple non-communicable disease, such as obesity, diabetes, and related cardiovascular risks represent a significant challenge across the globe, and early intervention is key to curbing the progression of these diseases. Low-grade inflammation is characterized by a subtle but persistent elevation of circulating proteins and is a known risk-factor for the progression of metabolic disease complications. Low-grade inflammation can however be highly variable from one subject to another and there are no therapies or interventions individually targeting it. The project will rely on a large national cohort of 3000 individuals to understand factors related to low-grade chronic inflammation and generate biomarkers. A clinical trial within this population also aims to demonstrate the effectiveness of personalized nutrition to reduce chronic low-grade inflammation. This approach not only aims to improve the management of existing cardiometabolic conditions but also to pave the way for preventative strategies, reducing cardiometabolic disease burden.

Collaboration for Innovation

“Integrative Phenomics is excited to collaborate with Prof. Clément and her NutriOmics Lab on this transformative project. Our shared vision on targeting low-grade inflammation to prevent or manage metabolic disease and related risks is at the core of this partnership. The project is the perfect opportunity to combine their clinical and biological expertise with our approach to personalized nutrition using our existing models and algorithms within our in silico Modeling Core (IMC©). The IMC already powers solutions in personalized nutrition for cardiometabolic disease, and this will allow us to target disease prevention,” stated Timothy Swartz, Scientific Program Director at Integrative Phenomics.

Prof. Clément added, “This collaboration represents a significant step forward in our ongoing efforts to understanding the link between metabolism and inflammation in nutrition-related diseases. Personalized nutrition has the potential to change the way we approach these common disorders and their prevention.”

Looking to the Future

The project started in April 2023 and runs for over three years. The outcomes are expected to have a profound impact on the nutrition and health sector by identifying novel biomarkers and providing evidence-based, personalized nutrition technology for disease prevention with recommendations that are seamlessly integrated into everyday life.